

**A REVIEW ON GAMMA-AMINO BUTYRIC ACID (GABA) AND ITS RECEPTORS****M.SUDHEER KUMAR\* AND I. J. KUPPAST**

Department of Pharmacology, National College of Pharmacy, Balraj-Urs Road, Shimoga-577201, Karnataka, India

**ABSTRACT**

The inhibitory neurotransmitter,  $\gamma$ -aminobutyric acid (GABA), activates a variety of receptors in all areas of the central nervous system (CNS). GABA acts at inhibitory synapses in the brain by binding to specific transmembrane receptors in the plasma membrane of both pre and postsynaptic neuronal processes. There are three classes of GABA receptors. GABA<sub>A</sub> and GABA<sub>C</sub> receptors are ionotropic in nature (i.e., their activation results in enhanced membrane ion conductance) and GABA<sub>B</sub> receptor is metabotropic type of receptor (i.e., their activation results in increased intracellular levels of second messenger). GABA is present in high concentrations (millimolar) in many brain regions. The GABA<sub>A</sub> receptor is a complex structure and includes the five major binding domains. These include binding sites localized in or near the Cl<sup>-</sup> channel for GABA, benzodiazepines, barbiturates and picrotoxin as well as binding sites for the anesthetic steroids. GABA<sub>B</sub> receptors (GABA<sub>B</sub>) are metabotropic transmembrane receptors for gamma-aminobutyric acid (GABA) that are linked via G-proteins to potassium channels. These GABA<sub>B</sub> receptors are activated by baclofen. In addition to the GABA<sub>B</sub> receptors there is a distinct class of ligand gated ion channels that are activated by GABA, referred to as the GABA<sub>C</sub> receptor. The GABA<sub>C</sub> receptors are activated by cis-aminocrotonic acid (CACA), which is not recognised by either the GABA<sub>A</sub> or GABA<sub>B</sub> receptors. GABA<sub>C</sub> receptors are expected to mediate the lateral inhibition of light responses and have been shown to inhibit transmitter release at bipolar cell terminals. The pharmacology of these novel subtypes of GABA receptors may yield important therapeutic agents.

**KEY WORDS** : Gama-aminobutyric acid (GABA), Ionotropic, Metabotropic, Baclofen, Cis-aminocrotonic acid (CACA)**M.SUDHEER KUMAR**

Department of Pharmacology, National College of Pharmacy, Balraj-Urs Road, Shimoga-577201, Karnataka, India

\*Corresponding author

## INTRODUCTION

### GAMMA-AMINO BUTYRIC ACID (GABA)

GABA is the major inhibitory amino acid transmitter of the mammalian central nervous system and it is present in some 25-50% of all neurones<sup>1</sup>.  $\gamma$ -aminobutyric acid (GABA) is the chief inhibitory neurotransmitter in mammalian central nervous system and it plays an important role in regulating the neuronal excitability throughout the nervous system.

Several amino acids are found in high concentrations in brain, and some have been established as neurotransmitters. *L*-

*Glutamic* acid (glutamate) is the major neurotransmitter for fast excitatory synaptic transmission, whereas the  $\gamma$ -aminobutyric acid (GABA) is considered as a major neurotransmitter for fast inhibitory synaptic transmission. Glycine is a secondary rapid inhibitory neurotransmitter, especially in the spinal cord<sup>2, 3</sup>. GABA acts at inhibitory synapses in the brain by binding to specific transmembrane receptors in the plasma membrane of both pre and postsynaptic neuronal processes. This binding causes the opening of ion channels to allow the flow of either negatively charged chloride ions into the cell or positively charged potassium ions out of the cell. Depending on which ion channels open, the membrane potential is either hyperpolarized or repolarized. This action results in a negative change in the transmembrane potential, usually causing hyperpolarization. Neurons that produce GABA as their output are called GABAergic neurons, and have chiefly inhibitory action<sup>4</sup>. Most of the early studies, carried out with iontophoretic application of GABA in the CNS, indicated that it generally produced inhibitory hyperpolarizing responses on neurones, which were blocked competitively by the alkaloid bicuculline. The hyperpolarizing response is due to an increase in the chloride conductance of the neuronal membrane allowing chloride ions to flow down their electrochemical gradient into the cell. However, in the late 1970s, Bowery and his colleagues, in attempts to identify GABA receptors on peripheral nerve

terminals, noted that GABA application reduced the evoked release of noradrenaline in the rat heart and that this effect was not blocked by bicuculline. This action of GABA was mimicked by baclofen, 4-amino-3-(4-chlorophenyl) butanoic acid, a compound that had no effect on chloride conductance in central neurones. The new receptor was named GABA<sub>B</sub> to differentiate it from its more familiar cousin, which was termed GABA<sub>A</sub>. The GABA<sub>C</sub> receptor had a rather more difficult birth.

In an attempt to discover which conformation of GABA was responsible for activating the receptor, Johnson and his colleagues synthesised a number of conformationally restricted analogues of GABA and noted that *cis*-4-aminocrotonic acid (CACA), which has a partially folded conformation, depressed the firing of cat spinal neurones in a bicuculline insensitive manner. These depressant effects could not be reproduced by baclofen<sup>5</sup>, suggesting pharmacology distinct from that of either GABA<sub>A</sub> or GABA<sub>B</sub> receptors. This receptor is known as GABA<sub>C</sub>. The DNAs that encode these receptor proteins have now been identified, providing not only a facile means for their molecular characterisation but also a significant stimulus for our attempts to understand their physiological importance.

### SYNTHESIS, RELEASE, UPTAKE AND METABOLISM OF GABA

GABA is formed *in vivo* by a metabolic pathway referred to as the GABA shunt. The GABA shunt is a closed-loop process with the dual purpose of producing and conserving the supply of GABA. GABA is present in high concentrations (millimolar) in many brain regions. The first step in the GABA shunt is the transamination of  $\alpha$ -ketoglutarate, formed from glucose metabolism in the Krebs cycle by GABA  $\alpha$ -oxoglutarate transaminase (GABA-T) into *L*-glutamic acid<sup>6</sup>. Glutamic acid decarboxylase (GAD) catalyzes the decarboxylation of glutamic acid to form GABA. GAD is expressed only in GABAergic neurons and in certain peripheral tissues

which are also known to synthesize GABA. Like most neurotransmitters, GABA is stored in synaptic vesicles and is released in a  $\text{Ca}^{2+}$  dependent manner upon depolarization of the presynaptic membrane. Following release into synaptic cleft, GABA's actions are terminated principally by reuptake into presynaptic terminals and/or surrounding glial cells<sup>7</sup>. In the nerve terminal, GABA is stored in vesicles by a unique sodium-independent, ATP-dependent transport system that is selective for GABAergic neurons<sup>8, 9</sup>. This uptake system is biochemically and pharmacologically distinct from the neuronal and glial membrane high-affinity transport system and is driven by an electrochemical proton gradient<sup>10-12</sup>. GABA in vesicles and, perhaps, in the cytoplasm is released into the synaptic cleft upon depolarization of the terminal by a calcium dependent mechanism. After release, GABA diffuses across the

synaptic cleft to interact with postsynaptic GABA receptors. GABA is inactivated by diffusion and by a high-affinity, sodium-dependent transport system into synaptic terminals and glial cells. The reuptake of GABA occurs via highly specific transmembrane transporters which have recently been shown to be members of a large family of  $\text{Na}^+$  dependent neurotransmitter transporters. GABA uptake is temperature- and ion-dependent<sup>13</sup> (both  $\text{Na}^+$  and  $\text{Cl}^-$  ions are required for optimal uptake). GABA is also metabolized by GABA-T to form succinic semi-aldehyde. This transamination will regenerate glutamate when it occurs in the presence of  $\alpha$ -ketoglutarate. Succinic semialdehyde is oxidized by succinic semi-aldehyde dehydrogenase (SSADH) to succinic acid which then re-enters the Krebs cycle<sup>13</sup>.

#### Synthesis of GABA by GABA shunt<sup>41</sup>




Figure 1

***GABA shunt is a closed-loop process with the dual purpose of producing and conserving the supply of GABA. The first step in the GABA shunt is the transamination of  $\alpha$ -ketoglutarate, formed from glucose metabolism in the Krebs cycle by GABA  $\alpha$ -oxoglutarate transaminase (GABA-T) into L-glutamic acid<sup>6</sup>. Glutamic acid decarboxylase (GAD) catalyzes the decarboxylation of glutamic acid to form GABA. GAD is expressed only in GABAergic neurons and in certain peripheral tissues which are also known to synthesize GABA.***

#### GABA RECEPTORS - PHYSIOLOGY AND PHARMACOLOGY

The GABA receptors are a class of receptors that respond to the neurotransmitter gamma-aminobutyric acid (GABA), the chief inhibitory neurotransmitter in the vertebrate central nervous system. There are three classes of

GABA receptors.  $\text{GABA}_A$  and  $\text{GABA}_C$  receptors are ionotropic (i.e., their activation results in enhanced membrane ion conductance),  $\text{GABA}_B$  receptor is metabotropic (i.e., their activation results in increased intracellular levels of second messenger)<sup>14, 15</sup>.  $\text{GABA}_A$  and  $\text{GABA}_C$  receptors

are ionotropic receptors leading to increased Cl<sup>-</sup> ion conductance, whereas GABA<sub>B</sub> receptors are metabotropic receptors which are coupled to G proteins and thereby indirectly alter membrane ion permeability and neuronal excitability. GABA receptors were widely distributed in mammalian brain and are in high concentration in cerebral cortex, hippocampus, basal ganglia, thalamus, cerebellum, and brainstem<sup>16</sup>.

### GABA<sub>A</sub> RECEPTOR

The GABA<sub>A</sub> receptor is one of ligand-gated ion channels responsible for mediating the effects of Gamma-Amino Butyric Acid (GABA). The rapid chloride current defined a physiologic receptor mechanism termed the GABA<sub>A</sub> receptor, also pharmacologically defined by the antagonist bicuculline, as well as picrotoxin, and the agonist muscimol. Thus, the GABA<sub>A</sub> receptor is a chloride channel regulated by GABA binding, and it is now grouped in the superfamily of ligand-gated ion channel receptors, which includes the well-characterized nicotinic acetylcholine receptor, present at the skeletal neuromuscular junction<sup>17, 18</sup>.

In ionotropic GABA<sub>A</sub> receptors, binding of GABA molecules to their binding sites in the extracellular part of receptor triggers the opening of a chloride ion-selective pore. The increased chloride conductance drives the membrane potential towards the reversal potential of the Cl<sup>-</sup> ion which is about -65 mV in neurons, inhibiting the firing of new action potentials<sup>19</sup>.

The GABA<sub>A</sub> receptors are the major players in CNS function and relevance to psychopharmacology. Activation of the GABA<sub>A</sub> receptor by agonist results in an increase in Cl<sup>-</sup> ion conductance via the receptor-gated ion channel or pore. This increase in Cl<sup>-</sup> ion conductance, which requires the binding and cooperative interaction of two molecules of GABA, is actually due to an increase in the mean open time of the Cl<sup>-</sup> ion channel itself<sup>20</sup>. (GABA activates the GABA<sub>A</sub> receptor at low micromolar concentrations, suggesting that it must be highly compartmentalized within


nervous tissue). The increase in Cl<sup>-</sup> ion conductance observed following activation of GABA<sub>A</sub> receptors results in a localized hyperpolarization of the neuronal membrane and therefore leads to an increase in the "threshold" required for excitatory neurotransmitters to depolarize the membrane in order to generate an action potential. This decrease in neuronal membrane "excitability" results in the inhibitory actions of GABA.

### MOLECULAR STRUCTURE OF GABA<sub>A</sub> RECEPTORS

The GABA<sub>A</sub> receptor is a complex structure and includes the five major binding domains. These include binding sites localized in or near the Cl<sup>-</sup> channel for GABA, benzodiazepines, barbiturates and picrotoxin as well as binding sites for the anesthetic steroids. These binding domains modulate receptor response to GABA stimulation. In addition, other drugs, including volatile anesthetics, ethanol and penicillin, have been reported to have an effect on this receptor<sup>21</sup>. An integral part of this complex is the Cl<sup>-</sup> channel. The GABA-binding site is directly responsible for opening the Cl<sup>-</sup> channel. A variety of agonists binds to this site and elicits GABA-like responses. One of the most useful agonists is the compound muscimol, a naturally occurring

GABA analogue isolated from the psychoactive mushroom *Amanita muscaria*. It is a potent and specific agonist at GABA<sub>A</sub> receptors and has been a valuable tool for pharmacological and radioligand-binding studies<sup>22, 23</sup>. Other GABA agonists include isoguvacine, 4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridin-3-ol (THIP), 3-aminopropane-sulfonate and imidazoleacetic acid<sup>23</sup>. The classical GABA<sub>A</sub>-receptor antagonist is the convulsant bicuculline, which reduces current by decreasing the opening frequency and mean open time of the channel. It is likely that bicuculline produces its antagonistic effects on GABA<sub>A</sub>-receptor currents by competing with GABA for binding to one or both sites on the GABA<sub>A</sub> receptor.

### Structural model of the GABA<sub>A</sub> benzodiazepine receptor—chloride (Cl<sup>-</sup>) ionophore complex<sup>41</sup>



**Figure 2**

*The cut-away view of the GABA<sub>A</sub> demonstrates targets for a variety of compounds that influence the receptor complex. No specific drug receptor location is implied.*

#### **GABA<sub>A</sub> RECEPTOR IS THE MAJOR MOLECULAR TARGET FOR THE ACTION OF MANY DRUGS IN THE BRAIN**

Among these are benzodiazepines, intravenous and volatile anesthetics and possibly ethanol. Benzodiazepine receptor-binding sites copurify with the GABA-binding sites<sup>24</sup>. In addition, benzodiazepine receptors are immune precipitated with antibodies that were developed to recognize the protein containing the GABA-binding site<sup>25</sup>. This indicates that the benzodiazepine receptor is an integral part of the GABA<sub>A</sub> receptor Cl<sup>-</sup> channel complex.

Benzodiazepine agonists represent the newest group of agents in the general class of depressant drugs, which also includes barbiturates, that show anticonvulsant, anxiolytic and sedative—hypnotic activity. Well-known examples include diazepam and chlordiazepoxide, which often are prescribed for their anti-anxiety effects<sup>26</sup>. The mechanism of action of benzodiazepine agonists is to enhance GABAergic transmission. From electrophysiological studies, it is known that these benzodiazepines increase the frequency of channel opening in response to GABA, thus accounting for their pharmacological and therapeutic actions. In addition, the benzodiazepine site is coupled allosterically to the barbiturate and picrotoxin

sites<sup>27</sup>. Benzodiazepine receptors are heterogeneous with respect to affinity for certain ligands. A wide variety of nonbenzodiazepines, such as the  $\beta$ -carbolines, cyclopyrrolones and imidazopyridines, also bind to the benzodiazepine site.

Barbiturates comprise another class of drugs commonly used therapeutically for anesthesia and control of epilepsy. Phenobarbital and pentobarbital are two of the most commonly used barbiturates. Phenobarbital has been used to treat patients with epilepsy since 1912. Pentobarbital is also an anticonvulsant, but it has sedative side effects. Barbiturates at pharmacological concentrations allosterically increase binding of benzodiazepines and GABA to their respective binding sites<sup>27</sup>. Measurements of mean channel open times show that barbiturates act by increasing the proportion of channels opening to the longest open state (9 millisecond) while reducing the proportion opening to the shorter open states (1 and 3 millisecond), resulting in an overall increase in mean channel open time and Cl<sup>-</sup> flux.

Channel blockers, such as the convulsant compound picrotoxin, cause a decrease in mean channel open time. Picrotoxin works by preferentially shifting opening channels to the briefest open state (1 millisecond). Thus, both picrotoxin and

barbiturates appear to act on the gating process of the GABA<sub>A</sub> receptor channel, but their effects on the open states are opposite to each other. Experimental convulsants like pentylenetetrazol and the cage convulsant- butyl bicyclophosphorothionate (TBPS) act in a manner similar to picrotoxin, preventing Cl<sup>-</sup> channel permeability. The antibiotic penicillin is a channel blocker with a net negative charge. It blocks the channel by interacting with the positively charged amino acid residues within the channel pore, consequently occluding Cl<sup>-</sup> passage through the channel.

There have been numerous studies on the role of GABA<sub>A</sub> receptors in anesthesia. A considerable amount of evidence has been compiled to suggest that general anesthetics, including barbiturates, volatile gases, steroids and alcohols, enhance GABA-mediated Cl<sup>-</sup> conductance. A proper assessment of this phenomenon requires not only a behavioral assay of anesthesia but also *in vitro* models for the study of receptor function. In this regard, not only electrophysiological methods but also neurochemical measurements of Cl<sup>-</sup> flux and ligand binding have been useful. For example, a strong positive correlation exists between anesthetic potencies and the stimulation of GABA-mediated Cl<sup>-</sup> uptake. This is seen with barbiturates and anesthetics in other chemical classes<sup>28</sup>.

Comparison of ligand-gated ion channels that vary in sensitivity to anesthetic modulation, using the chimera and site-directed mutagenesis approach, has identified two amino acids in the membrane-spanning domains that are critical for anesthetic sensitivity<sup>29</sup>. Direct evidence of ethanol augmentation of GABA<sub>A</sub> receptor function, measured either by electrophysiological techniques or agonist-mediated Cl<sup>-</sup> flux, has been reported<sup>28, 30</sup>. The similarity between the actions of ethanol and sedative drugs such as benzodiazepines and barbiturates that enhance GABA action suggests that ethanol may exert some of its effects by enhancing the function of GABA<sub>A</sub> receptors. Ethanol potentiation of GABA<sub>A</sub> receptor function appears to be dependent upon the cell type tested and the method of

assay. This suggests that the ethanol interaction may be specific for certain receptor subtypes and/or that it may be an indirect action.

### GABA<sub>B</sub> RECEPTORS

GABA also activates metabotropic GABA<sub>B</sub> receptors, which are widely distributed within the central nervous system and also in peripheral autonomic terminals. GABA<sub>B</sub> receptors (GABA<sub>B</sub>) are metabotropic transmembrane receptors for gamma-aminobutyric acid (GABA) that are linked via G-proteins to potassium channels<sup>31</sup>.

Their activation causes an inhibition of both basal and stimulated adenylatecyclase activity together with a decrease in Ca<sup>2+</sup> and an increase in K<sup>+</sup> conductance in neuronal membranes. The receptors are activated by baclofen, used in the treatment of spasticity, baclofen being the active isomer. There is evidence that GABA<sub>B</sub>receptor agonists may be useful in the treatment of pain and to reduce the craving for drugs of addiction. There is limited information on the therapeutic potential of GABA<sub>B</sub>receptor antagonists but there is support for the idea that they may prove valuable in the treatment of absence epilepsy and as cognition enhancers.

GABA<sub>B</sub> receptors are coupled indirectly to K<sup>+</sup> channels. When activated, these receptors can decrease Ca<sup>2+</sup> conductance and inhibit cAMP production via intracellular mechanisms mediated by G proteins. GABA<sub>B</sub> receptors can mediate both postsynaptic and presynaptic inhibition. Presynaptic inhibition may occur as a result of GABA<sub>B</sub> receptors on nerve terminals causing a decrease in the influx of Ca<sup>2+</sup>, thereby reducing the release of neurotransmitters<sup>32</sup>.

GABA<sub>B</sub>receptors couple to Ca<sup>2+</sup> and K<sup>+</sup> channels via G proteins and second messenger systems<sup>33,34</sup>. They are selectively activated by baclofen and are antagonized by phaclofen and 2-hydroxy saclofen. GABA<sub>B</sub> receptors do not respond to the known GABA<sub>A</sub> receptor modulators.

### GABA<sub>C</sub> RECEPTORS



In addition to the GABA<sub>B</sub> receptors there is a distinct class of ligand gated ion channels that are activated by GABA, referred to as the GABA<sub>C</sub> receptor. It is a subclass of ionotropic GABA receptors, insensitive to typical allosteric modulators of GABA<sub>A</sub> receptor channels such as benzodiazepines and barbiturates, was designated GABA<sub>C</sub> receptor<sup>35</sup>. The natural agonist GABA is about an order of magnitude more potent at the GABA<sub>C</sub> receptors than at the most common of the GABA<sub>A</sub> receptors.

The GABA<sub>C</sub> receptors are activated by cis-aminocrotonic acid (CACA), which is not recognised by either the GABA<sub>A</sub> or GABA<sub>B</sub> receptors, suggesting that they recognise the partially folded conformation of GABA. GABA receptors are not blocked by bicuculline and do not recognise the benzodiazepines, barbiturates or the neuroactive steroids but, like GABA<sub>A</sub> receptors are blocked by picrotoxin, while 1,2,5,6-tetrahydropyridine-4-yl methyl phosphinic acid (TPMPA) appears to inhibit GABA<sub>C</sub> receptors selectively<sup>36</sup>. Native responses of the GABA<sub>C</sub> receptor type occur in retinal bipolar or horizontal cells across vertebrate species. GABA<sub>C</sub> receptors are exclusively composed of ρ (rho) subunits that are related to GABA<sub>A</sub> receptor subunits. Although the term "GABA<sub>C</sub> receptor" is frequently used, GABA<sub>C</sub> may be viewed as a variant within the GABA<sub>A</sub> receptor family<sup>37</sup>.

#### **CACA (CIS-AMINOCROTONIC ACID) AS A SELECTIVE GABA, RECEPTOR LIGAND**

CACA is much more selective as a GABA, receptor ligand than the more potent TACA, which interacts strongly with a variety of macromolecules that recognize GABA. Unlike TACA, CACA is at best, a very weak GABA, receptor agonist and is neither a substrate for, nor an inhibitor of GABA, 2-oxoglutarate aminotransferase in extracts of rat brain mitochondria. In addition, it does not influence the activity of glutamate decarboxylase in rat brain extracts<sup>38</sup>. CACA is a weak substrate for a transporter that transports GABA, p-alanine and nipecotic acid in glial cells isolated from guinea-pig retina<sup>39</sup>. This is consistent with the idea that

CACA, p-alanine, nipecotic acid and GABA are substrates for a common transporter that may be related to the GAT-3 transport protein cloned from rat CNS. CACA is tenfold weaker as a substrate for the transporter than as a partial agonist for GABA, receptors<sup>39</sup>.

The most potent competitive antagonists of GABA, responses are 3-APMPA [3-aminopropyl (methyl) phosphinic acid], 3-APPA (3-aminopropyl phosphinic acid) and 3-APA (3-aminopropyl phosphonic acid).

Recent evidence indicates that GABA<sub>C</sub> receptors are composed of the recently discovered p subunit. In 1991, Cutting and colleagues cloned the p1 subunit from a human cDNA library. This was the first member of a new family of GABA-receptor subunits and is expressed at high levels in the retina. p<sub>1</sub> and p<sub>2</sub> share 74% amino acid sequence identity, but only 30-38% when compared with other GABA-receptor subunits<sup>40</sup>.

GABA<sub>C</sub> receptors display characteristic activation, desensitization, conductance and gating properties that distinguish them clearly from GABA<sub>A</sub> receptors. GABA<sub>C</sub> receptors are expected to mediate the lateral inhibition of light responses and have been shown to inhibit transmitter release at bipolar cell terminals.

#### **CONCLUSION**

Interest in the receptors for GABA, the major inhibitory transmitter in the CNS, has been developed, with varying degrees of enthusiasm, over the past 40 years. We now have agonists and antagonists which allow us to differentiate, experimentally at least, between responses mediated by the three pharmacologically distinct receptor families with which they interact. The possible mechanism of action of GABA<sub>A</sub> and GABA<sub>C</sub> receptors which are ionotropic receptors include the increased Cl<sup>-</sup> ion conductance, whereas for GABA<sub>B</sub> receptors (metabotropic receptors) which are coupled to G proteins and thereby altering indirectly membrane ion permeability and neuronal excitability. The information base is most extensive for the

GABA receptors, driven largely by observations that these proteins are the targets for a number of drugs with significant clinical importance. The expansion continues with the conviction that this almost bewildering complexity can be harnessed for the next generation of pharmacological agents with a more restricted profile of activity. The developments over the past 7 years or more have delivered a promissory note that is producing significant investment and many hold real conviction in their future.

## ACKNOWLEDGMENT

The authors express their sincere thanks to the Principal, National College of Pharmacy, Shimoga, Karnataka, India and the Board of Management, National Education Society, Shimoga for their kind support and providing necessary facilities to carryout this research.

## REFERENCES

1. Fagg, G.E. and Foster, A.C.: Amino acid neurotransmitters and their pathways in the mammalian central nervous system. *Neuroscience*, 9:701-719, (1983)
2. R.W. Olsen and T.M. DeLorey. GABA and glycine. In: G.J. Siegel, B.W. Agranoff, R.W. Albers, *et al.*, (eds.), *Basic neurochemistry*, 6<sup>th</sup>Edn, Lippincott Williams & Wilkins, New York, 2002, pp.335–346.
3. Macdonald RL and Olsen RW, GABA<sub>A</sub> receptor channels. *Annu Rev Neurosci*, 17: 569–602, (1994).
4. French-Constant RH, Rocheleau TA, Steichen JC, Chalmers AE, A point mutation in a Drosophila GABA receptor confers insecticide resistance. *Nature*, 363 (6428): 449–451, (1993).
5. Curtis, D. R. , Duggan, A. W. , Felix, D. , and Johnston, G. A. K. , *Nature*, 226, 1222 (1970).
6. McGeer PL and McGeer EG Amino acid neurotransmitters. In G. Siegel, B. Agranoff, R. W. Albers, and P. Molinoff (eds.), *Basic Neurochemistry*, 4<sup>th</sup>Edn, Raven Press, New York, 1989, pp.311–332.
7. Guastella J, Nelson N, Nelson H, *et al.*, Cloning and expression of a rat brain GABA transporter. *Science*, 249:1303–1306, (1990).
8. Fykse EM and Fonnum F, Uptake of gamma-aminobutyric acid by a synaptic vesicle fraction isolated from rat brain. *J. Neurochem*, 50: 1237-1242, (1988).
9. Hell JW, Maycox PR, Stadler H, and Jahn R, Uptake of GABA by rat brain synaptic vesicles isolated by a new procedure. *EMBO J*, 7(10):3023-3029, (1988).
10. Wood JD and Sidhu HS, Uptake of gamma-aminobutyric acid by brain tissue preparations: a reevaluation. *J. Neurochem*, 46:739-744, (1986).
11. Debler EA and Lajtha A, High-affinity transport of gamma-aminobutyric acid, glycine, taurine, L-aspartic acid, and L-glutamic acid in synaptosomal (P2) tissue: a kinetic and substrate specificity analysis. *J. Neurochem*, 48:1851-1856, (1987).
12. Krogsgaard-Larsen P, Falch E, Larsson OM, and Schousboe A, GABA uptake inhibitors: relevance to antiepileptic drug research. *Epilepsy Res*, 1:77-93, (1987).
13. Guastella J, Nelson N, Nelson H, *et al.*, Cloning and expression of a rat brain GABA transporter. *Science*, 249:1303–1306, (1990).
14. Bormann J, Electrophysiology of GABA<sub>A</sub> and GABA<sub>B</sub> receptor subtypes. *Trends Neurosci*, 11:112–116, (1988).
15. Macdonald RL, Twyman RE, Biophysical properties and regulation of GABA<sub>A</sub> receptor channels. *Semin Neurosci*, 3:219–230, (1991).
16. Young, Anne B Chu and Dorothy, Distribution of GABA A and GABA B receptors in mammalian brain: Potential targets for drug development. *Drug*



- Development Research, 21(3): 161-167, (1990).
17. Schofield PR, Darlison MG, Fujita N, *et al.*, Sequence and functional expression of the GABA<sub>A</sub> receptor shows a ligand gated receptor superfamily. *Nature*,328:221–227, (1987).
  18. Olsen RW and Tobin AJ, Molecular biology of GABA<sub>A</sub> receptors. *FASEB J*,4:1469–1480, (1990).
  19. Tomiko SA, Taraskevich PS and Douglas WW, GABA acts directly on cells of pituitary pars intermedia to alter hormone output. *Nature*,301(5902): 706–707, (1983).
  20. Macdonald RL and Twyman RE, Biophysical properties and regulation of GABA<sub>A</sub> receptor channels. *Semin Neurosci*, 3:219–230, (1991).
  21. Harris RA, Mihic SJ, Dildy-Mayfield JE and Machu TK, Actions of anesthetics on ligand-gated ion channels: Role of receptor subunit composition. *FASEB J*, 9:1454–1462, (1995).
  22. Johnston GAR, GABA<sub>C</sub> receptors: Relatively simple transmitter-gated ion channels? *Trends Pharmacol. Sci.*,17:319–323, (1996).
  23. P. Krosggaard-Larsen, L. Nielsen and E. Falch. The active site of the GABA receptor. In: R.W. Olsen and J. C. Venter (eds.), *Benzodiazepine/ GABA Receptors and Chloride Channels*, Alan R. Liss, New York, 1986, pp.73–95.
  24. Sigel E, Stephenson FA, Mamalaki C and Barnard EA, A  $\gamma$ -aminobutyric acid/benzodiazepine receptor complex of bovine cerebral cortex: Purification and partial characterization. *J. Biol. Chem.*, 258:6965–6971, (1983).
  25. Fritschy JM and Mohler H, GABA<sub>A</sub> receptor heterogeneity in the adult rat brain: Differential regional and cellular distribution of seven major subunits. *J. Comp. Neurol.*, 359:154–194, (1995).
  26. S. J. Enna and N. G. Bowery, Ed. *The GABA Receptors*, 2<sup>nd</sup>Edn, Clifton, Humana Press, 1997.
  27. Olsen RW, Sapp DW, Bureau MH, Turner D M and Kokka N, Allosteric actions of central nervous system depressants including anesthetics on subtypes of the inhibitory  $\gamma$ -aminobutyric acid<sub>A</sub> receptor—chloride channel complex. *Ann. N. Y. Acad. Sci.*, 625:145–154, (1991).
  28. Harris RA, Mihic SJ, Dildy-Mayfield JE and Machu TK, Actions of anesthetics on ligand-gated ion channels: Role of receptor subunit composition. *FASEB J*, 9:1454–1462, (1995).
  29. Mihic SJ, Ye Q, Wick MJ *et al.*, Sites of alcohol and volatile anesthetic action on GABA<sub>A</sub> and glycine receptors. *Nature*, 389:385–389, (1997).
  30. Suzdak PD, Schwartz RD, Skolnick P and Paul SM, Ethanol stimulates gamma-aminobutyric acid receptor-mediated chloride transport in rat brain synaptoneurosomes. *Proc. Natl. Acad. Sci. USA*, 83:4071–4075, (1986).
  31. Chen K, Li H, Ye N, Zhang J and Wang J, Role of GABA<sub>B</sub> receptors in GABA and baclofen-induced inhibition of adult rat cerebellar interpositus nucleus neurons in vitro. *Brain Res Bull*,67(4): 310–318, (2005).
  32. Kaupmann K, Huggel K, Heid J, *et al.*, Expression cloning of GABA<sub>B</sub> receptors uncovers similarity to metabotropic glutamate receptors. *Nature*, 386:239–246, (1997).
  33. Bowery NG, GABA<sub>B</sub> receptors and their significance in mammalian pharmacology. *Trends Pharmacol Sci*,10:401-407, (1989).
  34. Bowery NG, GABA<sub>B</sub> receptor pharmacology. *Annu Rev Pharmacol Toxicol*,33: 109-147, (1993).
  35. Zhang D, Pan ZH, Awobuluyi M and Lipton SA, Structure and function of GABA(C) receptors: a comparison of native versus recombinant receptors. *Trends Pharmacol. Sci.*,22 (3): 121–132, (2001).
  36. Drew CA, Johnston GA and Weatherby RP, Bicuculline-insensitive GABA receptors: studies on the binding of (-)-baclofen to rat cerebellar membranes. *Neurosci. Lett.*,52 (3): 317–321, (1984).
  37. Johnston GAR, Curtis DR, Beart PM, Game CJA, McCulloch RM and Twitchin B, Cis - and trans-4-aminocrotonic acid as

- GABA analogues of restricted conformation. *JNeurochem.*, 24:157-160, (1975).
38. Johnston GAR, GABA<sub>C</sub> receptors: relatively simple transmitter-gated ion channels? *Trends Pharmacol Sci.*, 17:319-323, (1996).
  39. Woodward RM, Polenzani L and Miledi R, Characterization of bicuculline/baclofen-insensitive (p-like)  $\gamma$ -aminobutyric acid receptors expressed in *Xenopus oocytes*. II. Pharmacology of  $\gamma$ -aminobutyric acid, and T-aminobutyric acid receptor agonists and antagonists. *MolPharmacol.*, 43:609-625, (1993).
  40. Cutting GR, Lu L, O'Hara BF, Kasch LM, Montrose Rafi, zadeh C, Donovan DM *et al.*, Cloning of the T-aminobutyric acid (GABA)  $\rho$ , cDNA: a GABA receptor subunit highly expressed in the retina. *ProcNatlAcadSci*, 88: 2673-2677, (1991).
  41. Siegel GJ, Agranoff BW, Albers RW, *et al.*, Ed. Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 6<sup>th</sup>Edn, Lippincott-Raven Publishers, (1999).